As transactions are sensitive strategic processes, names of companies and executives in all MotionHall case studies are anonymized.
The CEO of a pre-clinical gene medicine platform company engaged MotionHall's professional tools and services for dealmakers on the question of how to optimize the value of their platform through in-house development vs. partnering and out-licensing.
For the purposes of this anonymized case study produced in concert with the CEO, we will call this company "Sycamore Therapeutics".
There are several opportunities that present themselves to a platform company like Sycamore Therapeutics that the CEO, BD team and Board Members will all want to understand.
There’s the ability to develop assets themselves from development, and possibly through to commercialization. However, this is resource intensive, particularly constrained by the limited intellectual resources and financial capital of a start-up. Yes, the asset and the value it generates are completely under the control of the company, yet this approach doesn’t fully leverage the potential of a platform with a broad applicability across multiple therapeutic areas.
This is where focused and informed deal-making strategy can maximize the value generation from such a platform. By licensing the platform to multiple partners, each with a defined area of focus and expertise in generating assets, the company has the potential to capture significant value and help larger populations of patients in need.
The problem here is: how can you, as a leader of a platform company, select the right therapeutic areas (or otherwise divided segments of the total available market) for partnering? Furthermore, where should your company be developing validating science in order to open up specific markets for lucrative deals?
Using MotionHall's tools and technology, like Sycamore Therapeutics’ CEO did, you may evaluate complex questions like these by looking at the intersection of three critical elements:
For Sycamore Therapeutics, the gene medicine company had demonstrated early biomarker data in multiple tissues with the potential for effective delivery; this opened up many possible markets that were not the core focus of the company including cardiovascular, kidney, liver, muscular and neurological disorders.
This question weighed heavily on the CEO's mind at Sycamore Therapeutics, as they were looking to decide on where to apply their newly raised capital on developing in-house assets vs. gaining credibility through partnering with larger, well-established players in a range of therapeutic areas.
Sycamore's gene medicine platform had some clear constraints here, as the mechanism of the underlying technology meant that there was a specific set of pre-clinical tools and in-house expertise at potential partners required to develop successful assets.
In concert with the MotionHall Strategic Advisory Team, Sycamore's CEO planned and obtained a richly data-driven analysis drawing from both traditional and non-traditional inputs to address the three critical areas:
Sycamore's CEO walked away knowing exactly which indications and therapeutic areas to develop further in-house and which therapeutic areas to focus on partnering first. He significantly de-risked his pipeline strategy, as he now knows the newly raised capital will be used for targeting his partnering efforts in a therapeutic area with the highest likelihood of getting a deal done at a value on preferred timelines. Even more, he knows which therapeutic areas to prioritize after successfully partnering the first.